Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC-102 in Advanced Solid Tumors
NCT06710158Phase 1Recruiting
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of SC-102 in solid tumor (2 arms), sponsored by Tianjin ConjuStar Biologics Co., Ltd. Primary endpoints: Treatment-Emergent Adverse Events, Maximum Tolerated Dose and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
SC-102
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06710158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06710158.